Evaluation of the Mediduxâ„¢ Digital Health Application in Patients with HER2-positive Breast Cancer During Chemotherapy in Combination with HER2-targeted Therapy or Antibody-drug Conjugate Therapy.
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 585
- Registration Number
- NCT05425550
- Locations
- 🇨ðŸ‡
Seespital Horgen-Onkologie, Horgen, Switzerland
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 416
- Registration Number
- NCT04770272
- Locations
- 🇩🇪
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;, Bottrop, Germany
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 532
- Registration Number
- NCT03220178
- Locations
- 🇩🇪
University Hospital Mainz, Mainz, Germany
© Copyright 2024. All Rights Reserved by MedPath